Evidenced

Evidenced targets healthcare technology companies globally that stand to benefit from U.S. regulatory changes. The firm looks for startups whose growth accelerates when government agencies mandate new standards in areas like interoperability, reimbursement, or data privacy. It invests from early stage through growth, with a focus on helping non-U.S. companies enter and scale in the American market.

No. The firm's materials explicitly state that it selects "globally-sourced companies" that can benefit from U.S. regulatory tailwinds. This suggests a cross-border strategy where Evidenced identifies promising healthtech outside the United States, then positions those companies to succeed under American regulatory frameworks.

Evidenced invests across early stage — including start-ups — and growth stage. The exact check sizes and target ownership stakes are not publicly disclosed.

Evidenced has not publicly identified its investment committee, managing partners, or any team members on its website. The firm's decision-making structure remains unknown.

The firm's sourcing approach is not detailed publicly. Given its regulatory-arbitrage focus, it likely relies on networks within U.S. health-policy circles and international healthtech ecosystems to find companies that meet its thesis criteria.